Internal Medicine, Hematology & Oncology · Los Angeles, CA
NPI
1497717672
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1441 Eastlake Ave, Nor8302e
Los Angeles, CA, 90089
Phone (323) 865-3105
Groups this clinician bills Medicare through
Medicare paid, 2024
$51K
814 services
Medicare patients, 2024
189
Average age 73
Drug cost, 2024
$1.6M
434 prescriptions
Company payments, 2025
$27K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jorge J Nieva was code 99214 (office e&m - established), 302 times for 107 patients. In total Jorge J Nieva billed 814 services in 17 codes, and Medicare paid $51K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-11-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 302 | 107 | $74.98 | $23K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 185 | 72 | $13.72 | $2,537 |
| 99213 Office E&M - Established | Facility | 62 | 42 | $46.87 | $2,906 |
| 99215 Office E&M - Established | Facility | 52 | 43 | $117.98 | $6,135 |
| 99232 Hospital E&M - Subsequent | Facility | 34 | 16 | $62.33 | $2,119 |
| 99205 Office E&M - New | Facility | 28 | 28 | $134.32 | $3,761 |
| 99233 Hospital E&M - Subsequent | Facility | 28 | 14 | $97.87 | $2,740 |
| 99213 Office E&M - Established | Office | 26 | 18 | $54.97 | $1,429 |
| 99238 Hospital Discharge Management | Facility | 25 | 22 | $60.24 | $1,506 |
| 99223 Hospital E&M - Initial | Facility | 13 | 12 | $131.48 | $1,709 |
By year: 2022 $52K for 702 services; 2023 $45K for 577 services; 2024 $51K for 814 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jorge J Nieva prescribed most often to Medicare patients was Tagrisso (Osimertinib Mesylate), with 46 prescriptions and refills. In total Jorge J Nieva wrote 434 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | 46 | 46 | Under 11 | $727K |
| Levothyroxine Sodium Generic | 33 | 55 | Under 11 | $268 |
| Ondansetron Odt Ondansetron | 23 | 23 | Under 11 | $213 |
| Gilotrif Afatinib Dimaleate | 22 | 22 | Under 11 | $259K |
| Dexamethasone Generic | 18 | 18 | Under 11 | $255 |
| Minocycline Hcl Generic | 16 | 22 | Under 11 | $193 |
| Lorbrena Lorlatinib | 13 | 13 | Under 11 | $322K |
| Eliquis Apixaban | 13 | 13 | Under 11 | $7,694 |
| Xarelto Rivaroxaban | 12 | 14 | Under 11 | $7,842 |
| Prednisone Generic | 11 | 17 | Under 11 | $87.66 |
Brand drugs: 145 claims; generic drugs: 289 claims; opioid claims: 19.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jorge J Nieva $27K ($23K in general payments such as food, travel and fees and $3,820 for research) from 16 companies. The largest payer was Urogen Pharma, Inc. with $9,232.
| Company | Payments | Amount |
|---|---|---|
| Urogen Pharma, Inc. URGN | 7 | $9,232 |
| Pfizer Inc. PFE | 5 | $6,506 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $4,251 |
| Amgen Inc. AMGN | 3 | $3,820 |
| Daiichi Sankyo Inc. 4568.T | 3 | $1,172 |
| Caris MPI, Inc. | 2 | $1,028 |
| Gilead Sciences, Inc. GILD | 3 | $676 |
| Abbvie Inc. ABBV | 1 | $500 |
| EMD Serono, Inc. MRK.DE | 1 | $49.94 |
| Rigel Pharmaceuticals, Inc. RIGL | 1 | $40.25 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.